Serum Neuron Specific Enolase and S-100B Levels in Hemodialysis and Peritoneal Dialysis Patients

Abstract

Objective: Neuron-specific enolase (NSE) and S-100B are brain-derived proteins, and their levels increase in brain injury. The aim of the study wasto determine serum S-100B and NSE levels in patients with end-stage renal disease undergoing hemodialysis (HD) and peritoneal dialysis (PD) and todemonsrate how these levels were affected by the type of dialysis applied.Methods: The study group consisted of age- and gender-matched 20 patients undergoing HD, 26 patients undergoing continuous ambulatory PD(CAPD) and 21 healthy controls. Blood samples were obtained before and after dialysis in the HD patient group, and fasting blood samples wereobtained in the CAPD and control groups. The routine biochemical parameters were measured within two hours from all serum samples. Theremaining serum samples were stored at -80 °C until the day of analysis of the S-100B and NSE assays. Serum S-100B and NSE levels were measuredby chemiluminescence immunoassay method. Routine biochemistry tests were measured by colorimetric method using a biochemistry analyzer.Results: Serum S-100B (0.11±0.06 ng/mL in HD, 0.13±0.09 ng/mL in CAPD and 0.05±0.03 ng/mL in controls) and NSE (12.7±5.99 ng/mL in HD,9.26±5.52 ng/mL in CAPD and 6.82±2.36 ng/mL in controls) levels were higher in HD and CAPD groups compared to controls. S-100B and NSE levelswere higher after HD compared to before HD (p